FINWIRES · TerminalLIVE
FINWIRES

Cipla Arm Gets US FDA's Final Nod for Albuterol Sulfate Inhalation Aerosol; Shares Up 3%

By

-- Cipla USA Inc., a wholly-owned subsidiary of Cipla (NSE:CIPLA, BOM:500087), has received final approval from the U.S. Food and Drug Administration for its Albuterol Sulfate Inhalation Aerosol, according to a Thursday filing to the Indian stock exchanges.

The drug is a generic therapeutic equivalent of Ventolin HFA, marketed by GlaxoSmithKline.

Albuterol Sulfate Inhalation Aerosol is used to treat or prevent bronchospasm with reversible obstructive airway disease, and to prevent exercise-induced bronchospasm.

The product is expected to be launched in the first half of the financial year 2026-27 in the US.

According to IQVIA estimates, the total US albuterol market is valued at around $1.5 billion.

The company's shares were up over 3% in recent trade.

Related Articles

Treasury

Brief: Bank of Canada Governor Macklem's Press Conference on Policy Decision, MPR Starts

$^GSPTSE$.GSPTSE$$CXY
Sectors

US Total Weekly EIA Crude Oil Stocks Fall by 13.4 Million Barrels After Prior 2.2 Million Decrease

Research

Research Alert: Etsy: Solid Q1 As Etsy Marketplace Gms Growth Accelerates

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:ETSY delivered encouraging Q1 2026 results, with revenue of $631M beating the $617M consensus and adj-EBITDA of $185M beating $177M consensus. Etsy marketplace GMS returned to solid 5.5% Y/Y growth, marking a 540 bps improvement from Q4 2025 and the second consecutive quarter of expansion after years of decline. We believe this represents a potential inflection point led by mobile app improvements (personalization and search functions are getting better), with GMS growth accelerating to 11.2% Y/Y. For Q2 2026, ETSY guides for the third consecutive quarter of GMS growth of 3%-5% and full-year low-single digit GMS growth. We're encouraged by improving buyer metrics with active buyers at 86.6M (first sequential growth in two years) and GMS per buyer up 1.8% Y/Y. Take rate expanded 180 bps Y/Y to 25.7% while adj-EBITDA margins improved 100 bps Y/Y to 29.3%. We believe ETSY's strategic transformation is gaining traction but acknowledge an uncertain macro backdrop given the current geopolitical environment.

$ETSY